Detalhe da pesquisa
1.
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study.
Liver Int
; 39(10): 1852-1859, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31175707
2.
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.
Hepatology
; 53(2): 389-95, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21274861
3.
Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection.
Hepatology
; 49(2): 358-63, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19072829
4.
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.
N Engl J Med
; 352(25): 2609-17, 2005 Jun 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-15972867
5.
Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.
PLoS One
; 13(7): e0200568, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30063745